M.T.3
19.9.2023 17:01:29 CEST | Business Wire | Press release
Malignant Tumor Treatment Technologies, Inc. (Headquarters: Tokyo; President and CEO: Toshiyasu Miyazaki; “M.T.3”) announced today that the Japanese pharmaceutical regulatory agency, the Ministry of Agriculture, Forestry, and Fisheries, has granted approval for LAVURCHIN® as a radiation sensitizing agent for dogs with stage III or stage IV nasal cavity tumors.
Radiation therapy, a crucial treatment for malignant tumors that cannot be completely removed through surgery, has seen significant advancements in recent years in both human and veterinary medicine. However, challenges such as limitations on the number of radiation sessions and decreased effectiveness as tumors progress have highlighted the need for a radiation sensitizing agent to enhance treatment outcomes. Despite several candidate substances being studied, none have obtained pharmaceutical approval due to concerns about side effects.
After a long and challenging endeavor lasting over two and a half decades, "LAVURCHIN®" has emerged as a groundbreaking solution as the world’s first radiation sensitizing agent in the veterinary field approved by the Japanese Ministry of Agriculture, Forestry, and Fisheries (MAFF), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA). Derived from marine organisms, including sea urchins from Hokkaido, a northern region of Japan, and deep-sea seaweed, this innovative agent not only enhances the effects of radiation therapy but also minimizes damage to normal tissues, ensuring high safety standards.
"We are delighted to announce the approval of LAVURCHIN® as the world's first radiation sensitizing agent for dogs," said Toshiyasu Miyazaki, President and CEO of M.T.3. "This significant milestone is a testament to our commitment to advancing cancer treatment and improving the lives of both animals and humans. We will continue our endeavors to make LAVURCHIN® available to those in need around the world."
In parallel with the Japanese approval, M.T.3 is conducting clinical research on "LAVURCHIN®" in the United States, demonstrating a global perspective. The company envisions bringing this revolutionary product to markets worldwide, including the United States, Europe, and Asia. Furthermore, future expansion into human medicine is also being considered.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911165281/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Robbyant Upgrades and Open-Sources LingBot-VLA 2.0 as a Next-Generation Universal Brain for Embodied AI8.7.2026 10:11:00 CEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the upgrade and open-source release of LingBot-VLA 2.0. Building upon the foundation of LingBot-VLA 1.0 released in January 2026, this next-generation vision-language-action (VLA) model delivers significant leaps in morphological generalization, degrees of freedom (DoF) support, and deployment efficiency, delivering a more advanced “universal brain” for scalable real-world robotics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707394646/en/ LingBot-VLA 2.0 supports a wide range of robot morphologies While the embodied AI industry is witnessing rapid advancements in hardware and control systems, the lack of a truly universal brain remains a primary bottleneck for industrial-scale deployment. LingBot-VLA 2.0 addresses this critical gap by dramatically expanding its pre-training data and architectural capabilities. LingBot-VLA 2.0 was pre-trained on 60,000
TetraMem and SK hynix Showcase Successful Technology Collaboration Advancing Memory-Centric AI Computing8.7.2026 10:06:00 CEST | Press release
Joint achievement highlights how Analog In-Memory Computing can address the growing energy and thermal challenges of AI while laying the foundation for deeper collaboration on next-generation memory and computing architectures. TetraMem Inc., a leader in Analog In-Memory Computing (A-IMC) technology, and SK hynix Inc., a global leader in AI memory and semiconductor technologies, today announced the successful completion of a joint technology collaboration, highlighted by the publication of their research paper, “A Memristor-based In-Memory Computing SoC with Efficient Depthwise Convolution,” in Advanced Intelligent Systems. The work has also been selected as the cover feature of the journal, recognizing its technical innovation and potential impact on next-generation AI computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708244132/en/ The collaboration brings together SK hynix’s expertise in advanced memory technolo
Vultr and SUSE Launch Validated Full-Stack NVIDIA Enterprise AI Platform to Accelerate Production Deployments8.7.2026 10:00:00 CEST | Press release
SUSE AI Factory with NVIDIA on Vultr Infrastructure delivers integrated enterprise AI software, GPU acceleration, and global cloud infrastructure to move organizations from AI experimentation to secure production Vultr, the world's largest privately-held cloud infrastructure company, today announced the launch of SUSE AI Factory with NVIDIA on Vultr infrastructure, developed in partnership with SUSE. Announced alongside SUSE at the RAISE Summit in Paris, this validated, full-stack enterprise AI platform combines enterprise-grade AI software, advanced GPU acceleration, and global AI infrastructure into a single, production-ready solution. As organizations look to move AI workloads from experimentation into production, this joint solution eliminates the complexity of building AI stacks from scratch, allowing enterprises to deploy secure, scalable AI applications with ease. The solution combines software and infrastructure capabilities to help organizations securely and reliably advance a
NetApp Named Presenting Partner of 2026 NFL Madrid Game8.7.2026 10:00:00 CEST | Press release
League’s Official Intelligent Data Infrastructure Partner Extends Its Presence Across the NFL’s International Games The NFL today announced that the league’s Global Partner, NetApp (NASDAQ: NTAP), the Intelligent Data Infrastructure company, will return as Presenting Partner of the 2026 NFL Madrid Game, featuring the Atlanta Falcons taking on the Cincinnati Bengals at the Bernabéu Stadium — home to Real Madrid C.F. — on Sunday, Nov. 8. The multi-year announcement builds on NetApp’s role as the league’s Official Intelligent Data Infrastructure Partner and Presenting Partner of the inaugural NFL Madrid Game in 2025 and continues the company’s support of the league’s international games. “We are delighted to welcome NetApp back as Presenting Partner of the NFL Madrid Game,” said Rafa De Los Santos, country manager of NFL Spain. “Last year’s game at the Bernabéu was a landmark moment for the NFL in Spain, and with the Falcons and Bengals bringing two of the most exciting teams in football
MSIG Europe Selects Clearwater Analytics to Modernize Investment Operations8.7.2026 10:00:00 CEST | Press release
Selection extends MS&AD Group’s global relationship with Clearwater, bringing a unified platform for investment data, accounting, regulatory reporting, and analytics to MSIG Europe Clearwater Analytics today announced that MSIG Europe, a wholly owned subsidiary of MS&AD Insurance Group, has selected the Clearwater platform to modernize its operating model, unify data across the investment lifecycle, and meet the demands of the European regulatory environment, including Belgian GAAP, IFRS and Solvency II. European insurers are navigating the convergence of tightening regulatory demands, growing allocations to private markets, and the operational limits of fragmented legacy systems. The firms moving fastest are consolidating onto platforms that deliver daily accuracy, compliance automation, and integrated analytics at scale. MSIG is a wholly-owned subsidiary of Mitsui Sumitomo Insurance and a member of the MS&AD Insurance Group, one of Asia’s leading non-life insurance brands with a pres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom